Endothelial FAK as a therapeutic target in disease

Microvascular Research

Volumn 83, Issue 1, 2012, Pages 89-96

  Infusino, Giovanni A ^a   Jacobson, Jeffrey R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 CHLORO 2 (2 METHOXY 4 MORPHOLINOANILINO) 4 PYRIMIDINYLAMINO] N METHYLBENZAMIDE; AZW 592; BOSUTINIB; ETARACIZUMAB; FINGOLIMOD; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PF 562 271; PF 573 228; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; TAF 089; TAF 672; TUMSTATIN; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ATHEROSCLEROSIS; BREAST CANCER; CANCER GROWTH; CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE SCLEROSIS; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ACUTE LUNG INJURY; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIABETIC NEPHROPATHIES; ENDOTHELIAL CELLS; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; RESPIRATORY SYSTEM AGENTS; SIGNAL TRANSDUCTION;

EID: 82955248114     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2011.09.011     Document Type: Review

References (99)

1. Aronsohn M.S., et al. Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx. Laryngoscope 2003, 113:1944-1948.
2. Badger A.M., et al. Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis Rheum. 2001, 44:128-137.
3. Barter P.J., et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 2007, 357:2109-2122.
4. Bhattacharya S., et al. High tidal volume ventilation induces proinflammatory signaling in rat lung endothelium. Am. J. Respir. Cell Mol. Biol. 2003, 28:218-224.
5. Birukova A.A., et al. Paxillin is involved in the differential regulation of endothelial barrier by HGF and VEGF. Am. J. Respir. Cell Mol. Biol. 2009, 40:99-107.
6. Bolos V., et al. The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco. Targets Ther. 2010, 3:83-97.
7. Brinkmann V., et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 2010, 9:883-897.
8. Brooks P.C., et al. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571.
9. Brousseau M.E., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 2004, 350:1505-1515.
10. Camp S.M., et al. Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro. J. Pharmacol. Exp. Ther. 2009, 331:54-64.
11. Campone M., et al. Phase II study of single agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann. Oncol. 2011, June 23 [epub ahead of print].
12. Chang C.C., et al. Aryl-hydrocarbon receptor-dependent alteration of FAK/RhoA in the inhibition of HUVEC motility by 3-methylcholanthrene. Cell. Mol. Life Sci. 2009, 66:3193-3205.
13. Chen W., et al. Integrin beta4 attenuates SHP-2 and MAPK signaling and reduces human lung endothelial inflammatory responses. J. Cell. Biochem. 2010, 110:718-724.
14. Chodick G., et al. Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study. PLoS Med. 2010, 7:e1000336.
15. Clark E.A., et al. Integrin-mediated signals regulated by members of the rho family of GTPases. J. Cell Biol. 1998, 142:573-586.
16. Dale K.M., et al. Statins and cancer risk: a meta-analysis. JAMA 2006, 295:74-80.
17. Dasari V.R., et al. Downregulation of Focal Adhesion Kinase (FAK) by cord blood stem cells inhibits angiogenesis in glioblastoma. Aging (Albany NY). 2010, 2:791-803.
18. Gao X.P., et al. Role of NADPH oxidase in the mechanism of lung neutrophil sequestration and microvessel injury induced by Gram-negative sepsis: studies in p47phox-/- and gp91phox-/- mice. J. Immunol. 2002, 168:3974-3982.
19. Garcia J.G., et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J. Clin. Invest. 2001, 108:689-701.
20. Giunti S., et al. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. Am. J. Physiol. Renal Physiol. 2010, 299:F528-F535.
21. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
22. Gorbunova E.E., et al. VEGFR2 and Src kinase inhibitors suppress Andes virus-induced endothelial cell permeability. J. Virol. 2011, 85:2296-2303.
23. Guan J.L. Focal adhesion kinase in integrin signaling. Matrix Biol. 1997, 16:195-200.
24. Hahn C., Schwartz M.A. Mechanotransduction in vascular physiology and atherogenesis. Nat. Rev. Mol. Cell Biol. 2009, 10:53-62.
25. Haruna Y., et al. Fluvastatin reverses endothelial dysfunction and increased vascular oxidative stress in rat adjuvant-induced arthritis. Arthritis Rheum. 2007, 56:1827-1835.
26. Holinstat M., et al. Suppression of RhoA activity by focal adhesion kinase-induced activation of p190RhoGAP. J. Biol. Chem. 2006, 281:2296-2305.
27. Jacobson J.R., et al. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am. J. Respir. Cell Mol. Biol. 2004, 30:662-670.
28. Jacobson J.R., et al. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 288:L1026-L1032.
29. Johnson B.A., et al. Adhesion molecule expression in human synovial tissue. Arthritis Rheum. 1993, 36:137-146.
30. Kahana O., et al. The focal adhesion kinase (P125FAK) is constitutively active in human malignant melanoma. Oncogene 2002, 21:3969-3977.
31. Kawakami A., et al. Atorvastatin attenuates remnant lipoprotein-induced monocyte adhesion to vascular endothelium under flow conditions. Circ. Res. 2002, 91:263-271.
32. Kim T.J., et al. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer Biol. Ther. 2009, 8:2263-2272.
33. Kimball E.S., Gross J.L. Angiogenesis in pannus formation. Agents Actions 1991, 34:329-331.
34. Koshida R., et al. Role of focal adhesion kinase in flow-induced dilation of coronary arterioles. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2548-2553.
35. Kuoppala J., et al. Statins and cancer: a systematic review and meta-analysis. Eur. J. Cancer 2008, 44:2122-2132.
36. Lam K.S., et al. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995, 38:604-609.
37. Lee O.H., et al. Sphingosine 1-phosphate stimulates tyrosine phosphorylation of focal adhesion kinase and chemotactic motility of endothelial cells via the G(i) protein-linked phospholipase C pathway. Biochem. biophys. Res. Coomun. 2000, 268:47-53.
38. Lee J., et al. Conditional deletion of the focal adhesion kinase FAK alters remodeling of the blood-brain barrier in glioma. Cancer Res. 2010, 70:10131-10140.
39. Leung B.P., et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J. Immunol. 2003, 170:1524-1530.
40. Li S., et al. Fluid shear stress activation of focal adhesion kinase. Linking to mitogen-activated protein kinases. J. Biol. Chem. 1997, 272:30455-30462.
41. Li G., et al. Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity. Cancer Res. 2010, 70:10243-10254.
42. Lietha D., Eck M.J. Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation. PLoS One 2008, 3:e3800.
43. Liu, T. J., et al., 2007. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. 6, 1357-67.
44. Liu H.B., et al. Sphingosine-1-phosphate and its analogue FTY720 diminish acute pulmonary injury in rats with acute necrotizing pancreatitis. Pancreas 2008, 36:e10-e15.
45. Maeshima Y., et al. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J. Biol. Chem. 2000, 275:23745-23750.
46. Maeshima Y., et al. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. J. Biol. Chem. 2001, 276:31959-31968.
47. Maeshima Y., et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002, 295:140-143.
48. Malek A.M., et al. Hemodynamic shear stress and its role in atherosclerosis. JAMA 1999, 282:2035-2042.
49. Mandala S., et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002, 296:346-349.
50. Manes S., et al. Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase in regulation of cell motility. Mol. Cell. Biol. 1999, 19:3125-3135.
51. McVerry B.J., et al. Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. Am. J. Respir. Crit. Care Med. 2004, 170:987-993.
52. Mehta D., et al. Modulatory role of focal adhesion kinase in regulating human pulmonary artery endothelial barrier function. J. Physiol. 2002, 539:779-789.
53. Mita M., et al. Phase I study of E7820, an oral inhibitor of integrin {alpha}-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin. Cancer Res. 2010, 17:193-200.
54. Miyazaki T., et al. FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma. Br. J. Cancer 2003, 89:140-145.
55. Mortensen E.M., et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur. Respir. J. 2008, 31:611-617.
56. Moschos S.J., et al. Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma. J. Immunother. 2010, 33:316-325.
57. Mura M., et al. Vascular endothelial growth factor and related molecules in acute lung injury. J. Appl. Physiol. 2004, 97:1605-1617.
58. Muller H.C., et al. Simvastatin attenuates ventilator-induced lung injury in mice. Crit Care 2010, 14:R143.
59. Owens L.V., et al. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res. 1995, 55:2752-2755.
60. Paleolog E. Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis. Mol. Pathol. 1997, 50:225-233.
61. Peng X., et al. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am. J. Respir. Crit. Care Med. 2004, 169:1245-1251.
62. Poynter J.N., et al. Statins and the risk of colorectal cancer. N. Engl. J. Med. 2005, 352:2184-2192.
63. Qi J.H., et al. Tyrosine phosphatase SHP-2 is involved in regulation of platelet-derived growth factor-induced migration. J. Biol. Chem. 1999, 274:14455-14463.
64. Regoli M., Bendayan M. Expression of beta1 integrins in glomerular tissue of Streptozotocin-induced diabetic rats. Biochem. Cell Biol. 1999, 77:71-78.
65. Roberts W.G., et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res. 2008, 68:1935-1944.
66. Romer L.H., et al. Focal adhesions: paradigm for a signaling nexus. Circ. Res. 2006, 98:606-616.
67. Ruegg C., et al. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat. Med. 1998, 4:408-414.
68. Sakurama K., et al. Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor. Mol. Cancer Ther. 2009, 8:127-134.
69. Sato K., et al. In vivo lipid-derived free radical formation by NADPH oxidase in acute lung injury induced by lipopolysaccharide: a model for ARDS. FASEB J. 2002, 16:1713-1720.
70. Scandinavian Simvastatin Survival Study (4S) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994, 344:1383-1389.
71. Schaller M.D., et al. Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains. J. Cell Biol. 1995, 130:1181-1187.
72. Schlaepfer D.D., Hunter T. Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal adhesion kinase by Src-family protein tyrosine-kinases. Mol. Cell. Biol. 1996, 16:5623-5633.
73. Schlienger R.G., et al. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007, 27:325-332.
74. Schultze A., et al. TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis. Invest. New Drugs 2010, 28:825-833.
75. Shen T.L., et al. Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J. Cell Biol. 2005, 169:941-952.
76. Shepherd J., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 1995, 333:1301-1307.
77. Shikata Y., et al. Involvement of site-specific FAK phosphorylation in sphingosine-1 phosphate- and thrombin-induced focal adhesion remodeling: role of Src and GIT. FASEB J. 2003, 17:2240-2249.
78. Shikata Y., et al. S1P induces FA remodeling in human pulmonary endothelial cells: role of Rac, GIT1, FAK, and paxillin. J. Appl. Physiol. 2003, 94:1193-1203.
79. Slack-Davis J.K., et al. Cellular characterization of a novel focal adhesion kinase inhibitor. Biochem. Biophys. Res. Commun. 2007, 282:14845-14852.
80. Storgard C.M., et al. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J. Clin. Invest. 1999, 103:47-54.
81. Sun X., et al. Enhanced interaction between focal adhesion and adherens junction proteins: involvement in sphingosine 1-phosphate-induced endothelial barrier enhancement. Microvasc. Res. 2009, 77:304-313.
82. Szekanecz Z., et al. Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr. Opin. Rheumatol. 2010, 22:299-306.
83. Takeda I., et al. Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007, 98:890-899.
84. Tavora B., et al. Endothelial FAK is required for tumour angiogenesis. EMBO Mol. Med. 2010, 2:516-528.
85. Tonolo G., et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997, 20:1891-1895.
86. Traub O., Berk B.C. Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler. Thromb. Vasc. Biol. 1998, 18:677-685.
87. Tremblay L., et al. Focal adhesion kinase (pp 125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int. J. Cancer 1996, 68:164-171.
88. Usatyuk P.V., Natarajan V. Regulation of reactive oxygen species-induced endothelial cell-cell and cell-matrix contacts by focal adhesion kinase and adherens junction proteins. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 289:L999-L1010.
89. Veeravagu A., et al. Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme. Clin. Cancer Res. 2008, 14:7330-7339.
90. Vincent L., et al. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler. Thromb. Vasc. Biol. 2002, 22:623-629.
91. Vultur A., et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol. Cancer Ther. 2008, 7:1185-1194.
92. Vuori K. Integrin signaling: tyrosine phosphorylation events in focal adhesions. J. Membr. Biol. 1998, 165:191-199.
93. Yanagita K., et al. Hepatocyte growth factor may act as a pulmotrophic factor on lung regeneration after acute lung injury. J. Biol. Chem. 1993, 268:21212-21217.
94. Yang S., et al. Reactive oxygen species increased focal adhesion kinase production in pulmonary microvascular endothelial cells. Proc. West. Pharmacol. Soc. 2004, 47:54-56.
95. Yao X.M., et al. Simvastatin protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression. J. Endocrinol. Invest. 2010, 33:292-296.
96. Yuan S.Y. Protein kinase signaling in the modulation of microvascular permeability. Vascul. Pharmacol. 2002, 39:213-223.
97. Zhang F.L., Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 1996, 65:241-269.
98. Zhao X. Role of kinase-independent and -dependent functions of FAK in endothelial cell survival and barrier function during embryonic development. J. Cell Biol. 2010, 189:955-965.
99. Zhou H.F., et al. Alphavbeta3-targeted nanotherapy suppresses inflammatory arthritis in mice. FASEB J. 2009, 23:2978-2985.